All In Biotech

Drug Trial Radar · NCT04786873

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Multicenter, Open Label Trial to Investigate the Efficacy and Safety of a Single Oral Dose of 1.0 mg/kg Macimorelin Acetate as Growth Hormone Stimulation Test (GHST) in Pediatric Patients With Suspected Growth Hormone Deficiency (GHD)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Nov 16, 2021

Primary completion

Jun 13, 2024

Study completion Jun 13, 2024

Sponsor

Lead sponsor
AEterna ZentarisIndustry
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children. The stimulation test will use a new growth hormone stimulating substance called macimorelin. By now, only adults in the USA can get this new stimulation test. The results of this study are expected to help children and teenagers with suspected GHD to get the macimorelin stimulation test. The macimorelin test will be compared to a clonidine and an arginine test. Both are known standard stimulation tests. Altogether two macimorelin tests are planned to be performed in the study, to show how repeatable macimorelin tests results are (under a set of similar conditions).

Conditions

  • Growth Hormone Deficiency

Interventions

  • MacimorelinDrug

    Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.

  • ArginineDiagnostic test

    For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.

  • ClonidineDiagnostic test

    For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg. After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the Receiver Operator Characteristic curve (ROC AUC) based on GH concentration during GHST following macimorelin administrationTime frame: Derived from Cmax GH measurements collected in the time frame from 0 to 90 minutes after initial macimorelin GHST (visit 2 (day 0)) and GH adjudication status performed by the adjudication committee after visit 4 (between day 11 and day 58)).

Locations

45 sites in 11 countries. Site status is shown where the registry gives one.

  • Angel Wing Clinic For Children With Diabetes

    Tucson, Arizona

  • Pediatric Endocrine Associates, p.c.

    Greenwood Village, Colorado

  • John Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Emory Healthcare-Children's Center

    Atlanta, Georgia

  • St. Luke's Children's Endocrinology

    Boise, Idaho

  • University of Minnesota, Masonic Children's Hospital

    Minneapolis, Minnesota

  • The Children's Mercy Hospital - Broadway

    Kansas City, Missouri

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Children's Hospital at Montefiore

    The Bronx, New York

  • UNC Hospitals

    Chapel Hill, North Carolina

  • Alchemi Research Center

    Rosharon, Texas

  • Multicare Health System

    Tacoma, Washington

  • Yerevan State Medical University after Mkhitar Heraci

    Yerevan, Armenia

  • JSC Maritime Hospital

    Batumi, Georgia

  • National Institute of Endocrinology

    Tbilisi, Georgia

  • TSMU Givi Jvania Pediatric Academic Clinik

    Tbilisi, Georgia

  • Evangelisches Klinikum Bethel

    Bielefeld, Germany

  • Ospedale Pediatrico G. Salesi

    Ancona, Italy

  • Azienda Ospedaliero-Universitaria Anna Meyer

    Florence, Italy

  • Osp. dei Bambini V. Buzzi, ASST Fatebenefratelli Sacco

    Milan, Italy

  • Azienda Ospedaliero-Universitaria di Parma Ospedale dei Bambini Pietro Barilla, Clinica Pediatrica

    Parma, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • MED-POLONIA Sp.z o.o.

    Poznan, Poland

  • Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie

    Rzeszów, Poland

  • SPSK Nr 1 im. prof. Tadeusza Sokolowskiego PUM

    Szczecin, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu

    Wroclaw, Poland

  • Cen Med de Diagn si Trat Amb NEOMED

    Brasov, Romania

  • Sana Monitoring

    Bucharest, Romania

  • Medicover Hospitals

    Bucharest, Romania

  • Institutul de Endocrinologie "C.I. Parhon"

    Bucharest, Romania

  • Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Constanta

    Constanța, Romania

  • Spitalul Clinic Judetean de Urgenta "Sf. Spiridon" Iasi

    Iași, Romania

  • Spitalul Clinic Judetean Mures

    Târgu Mureş, Romania

  • Spitalul Cl. de Urgenta pentru Copii Louis Turcanu Timisoara

    Timișoara, Romania

  • University children's clinic Belgrade - Department of Endocrinology

    Belgrade, Serbia

  • Clinical Center Nis - Clinic for Children's Internal Medicine

    Niš, Serbia

  • Institute for Child and Youth Health Care of Vojvodina - Endocrinology

    Novi Sad, Serbia

  • National Institute of Children's Diseases

    Bratislava, Slovakia

  • Children's University Hospital Kosice

    Košice, Slovakia

  • National Institute of Endocrinology and Diabetology

    Ľubochňa, Slovakia

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.